Rybelsus guide
Rybelsus is a GLP-1 tablet. It contains semaglutide and is used for type 2 diabetes. It is not licensed as a UK weight-loss tablet, and this page does not provide personal prescribing advice.
A prescription tablet containing semaglutide.
Type 2 diabetes when blood sugar is not controlled well enough.
No. It is not licensed as a UK weight-loss medicine.
Rybelsus helps improve blood sugar control in adults with type 2 diabetes. It is used with diet and exercise.
It may be used on its own when metformin is unsuitable. It may also be used with other diabetes medicines.
It can only be obtained with a prescription.
| Item | Answer |
|---|---|
| Brand | Rybelsus |
| Active substance | Semaglutide |
| Form | Tablet taken by mouth |
| UK/EU use | Type 2 diabetes |
| Prescription status | Prescription-only medicine |
| Weight-loss licence | Not licensed as a UK weight-loss medicine |
Rybelsus is taken once daily. The dose starts low and is increased by the prescriber when needed.
Follow the patient leaflet and prescriber instructions. Do not change the dose yourself.
Important: Rybelsus has specific administration rules. Ask a pharmacist or prescriber if the instructions are unclear.
| Medicine | Form | Main UK use | Simple distinction |
|---|---|---|---|
| Rybelsus | Tablet | Type 2 diabetes | The oral semaglutide tablet. |
| Ozempic | Injection | Type 2 diabetes | Injectable semaglutide diabetes brand. |
| Wegovy | Injection | Weight management | Injectable semaglutide weight-management brand. |
The most common side effects include nausea, diarrhoea and low blood sugar when used with insulin or a sulphonylurea.
Get urgent medical help for severe abdominal pain or sudden eyesight changes. These symptoms need proper assessment.
Yes. Rybelsus is an oral GLP-1 receptor agonist medicine containing semaglutide.
Do not swap medicines yourself. Rybelsus and Wegovy have different licensed uses and routes.
Only use regulated services that require proper clinical checks and a legal prescription.
No. Tablet form does not automatically mean safer. Suitability depends on your medical history and other medicines.
UK status clarity
Use this matrix to separate what is available now, what is diabetes-only, what is pipeline, and what still needs a confirmed UK route.
| Product | Route | UK status | What to do now | Common confusion | Checked |
|---|---|---|---|---|---|
| Rybelsussemaglutide | oral tablet | Diabetes-use route | Licensed/used for type 2 diabetes in UK materials; do not treat it as a general UK weight-loss tablet route. | Users often confuse oral semaglutide for diabetes with a Wegovy-style weight-loss tablet. | 24 May 2026emc / MHRA materials |
| Oral semaglutide high-dosesemaglutide | oral tablet | Pipeline / not available | Track regulatory and provider updates; do not assume UK private supply from media coverage. | Searches for 25mg or Wegovy pill can imply availability before a UK route is clear. | 24 May 2026regulatory/public provider review |
| Wegovy pillsemaglutide | oral tablet | Pipeline / not available | Use injection Wegovy comparison for currently established UK Wegovy provider routes. | The brand Wegovy is established as an injection route in current UK public materials. | 24 May 2026MHRA Wegovy materials |
| Foundayo / orforglipronorforglipron | oral small molecule GLP-1 | UK status unclear | Treat as a watchlist product unless a UK regulator/provider route is confirmed. | US or media milestones do not automatically create a UK supply route. | 24 May 2026public regulatory watch |
| Orlistat / Xenical / Alliorlistat | capsule/tablet route | Available now | Compare as a non-GLP-1 tablet/capsule option with different evidence, side-effect and access context. | Often mixed into GLP-1 tablet searches even though it is not a GLP-1. | 24 May 2026UK medicine route context |